Blood Res.  2015 Jun;50(2):113-114. 10.5045/br.2015.50.2.113.

Successful re-treatment with azacitidine in a patient with low blast count AML transformed from MDS after suspension of this agent

• Niscola P
• Tendas A
• Scaramucci L
• Giovannini M
• Fratoni S
• de Fabritiis P

• KMID: 2172776
• DOI: http://doi.org/10.5045/br.2015.50.2.113

Abstract

No abstract available.

MeSH Terms

Azacitidine*
Humans
Azacitidine

Reference

1. Prébet T, Gore SD, Esterni B, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol. 2011; 29:3322–3327. PMID: 21788559.

2. Duong VH, Lin K, Reljic T, et al. Poor outcome of patients with myelodysplastic syndrome after azacitidine treatment failure. Clin Lymphoma Myeloma Leuk. 2013; 13:711–715. PMID: 24054159.

3. Niscola P, Tendas A, Cupelli L, et al. Dismal outcome of acute myeloid leukemia secondary to myelodysplastic syndrome and chronic myelomonocytic leukemia after azacitidine failure in a daily-life setting. Acta Haematol. 2015; 133:64–66. PMID: 25139255.

4. Voso MT, Breccia M, Lunghi M, et al. Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia. Eur J Haematol. 2013; 90:345–348. PMID: 23336938.

5. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89:2079–2088. PMID: 9058730.

6. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007; 25:3503–3510. PMID: 17687155.

7. Della Porta MG, Malcovati L, Strupp C, et al. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica. 2011; 96:441–449. PMID: 21134982.

8. Maurillo L, Buccisano F, Del Principe MI, et al. Treatment of acute myeloid leukemia with 20-30% bone marrow blasts. Mediterr J Hematol Infect Dis. 2013; 5:e2013032. PMID: 23795270.